NCT05703997View on ClinicalTrials.gov

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2029

Conditions
Small Cell Lung Carcinoma
Interventions
DIETARY_SUPPLEMENT

Cyclic, 5-day calorie restriction

Cyclic, 5-day, calorie-restricted (about 600 Kcal on day 1; about 300 Kcal on days 2 to 5), plant-based, low-protein, low-carbohydrate diet.

DRUG

Atezolizumab

Atezolizumab 1200 mg administered intravenously.

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale Tumori, Milan

All Listed Sponsors
collaborator

IFOM ETS - The AIRC Institute of Molecular Oncology

OTHER

collaborator

University of Milan

OTHER

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER